ClinicalTrials.gg
WithdrawnNCT07155980Updated Jan 7, 2026

A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants

A Phase 1 interventional study of GSM-779690T and Placebo in Healthy Adult Participants, sponsored by Acta Pharmaceuticals. Withdrawn at 1 site in United States. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Acta Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
The protocol is being withdrawn prior to enrollment due to a redesign of the study approach under the existing IND.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This is a randomized, double-blinded, placebo-controlled dose escalating first in human study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) of GSM-779690T. The study will have two parts: a single ascending dose (SAD) component and a multiple ascending dose (MAD) component. The goal of this study is to learn if GSM-779690T is safe and to assess the effects on levels of specific Aβ peptide isoforms in adults.

SAD: A total of 48 healthy volunteers are planned to be consented and enrolled to receive a single oral dose of GSM-779690T at increasing strengths or placebo in Cohorts 1 through 6.

MAD: A total of 48 healthy volunteers are planned to be consented and enrolled to receive multiple oral doses of GSM-779690T (doses will be informed by SAD data) in Cohorts 7 through 10. Cohort 10 will include healthy older-adults.

Participants who have signed an informed consent and meet screening eligibility requirements will be randomly assigned to receive a single oral dose of GSM-779690T or placebo with a 3:1 (active: placebo) ratio at each dose level. The decision to escalate between dose levels in the SAD and to proceed to the MAD will be based on Data Review Committee review of prior cohorts, safety, tolerability, and PK data. The study treatment, GSM-779690T, and all protocol assessments will be administered at the study site by trained study site personnel.

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • gamma-secretase modulator
  • Alzheimer's disease
  • Pharmacokinetics
  • pharmacodynamics
  • beta-amyloid
  • single ascending dose
  • multiple ascending dose
03

In context

Lead sponsor

Acta Pharmaceuticals is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Participants must meet all the following inclusion criteria to be eligible for enrollment:

  1. Healthy, cognitively typical, and aged 20-45 years (inclusive).
  2. Current (MMSE) score between 27 and 30 (inclusive) at screening.
  3. Able to provide their own written .
  4. Able to read, speak and understand English to ensure compliance with cognitive testing and study visit procedures.
  5. Must be ambulatory and be willing to remain domiciled in the clinic for the required study procedures.
  6. requirements:

    a. Women of (WOCBP) must agree to use a highly effective method of birth control (confirmed by the investigator) from enrollment, throughout the study duration, at 1 week after last dose of study treatment, and have a negative pregnancy test result at screening. Highly effective methods of birth control (those that can achieve a failure rate of less than 1% per year when used consistently and correctly) include: (i) Combined (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, (ii) Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable, (iii) Intrauterine device, (iv) Intrauterine hormone-releasing system, (v) Bilateral tubal occlusion, (vi) Sexual abstinence, ie, refraining from heterosexual intercourse (vii) Vasectomised sexual partner (provided that partner is the sole sexual partner of the WOCBP study participants and that the vasectomized partner has received medical assessment of the surgical success).

    b. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are . The following age-specific requirements apply: (i) Women \< 50 years old will be considered postmenopausal if they have been amenorrhoeic for >12 months following cessation of exogenous hormonal treatment and FSH levels are in the postmenopausal range (>40 IU/L). Until FSH is documented to be within menopausal range, the patient should be treated as a WOCBP.

    (ii) Women > 50 years old will be considered postmenopausal if they have been amenorrhoeic for >12 months following cessation of all exogenous hormonal treatment.

    c. Males with childbearing partners must be willing to practice sexual abstinence or use double-barrier protection during study treatment and until 1 week after the last dose of study treatment.

    The same Inclusion Criteria as listed above for the phase 1A SAD study applies to the adult cohorts (aged 20-45 years, inclusive) in phase 1B MAD Study. The following additional inclusion criteria apply to the older-adult Cohort 10 only:

8. Healthy, cognitively typical, aged 60-75 years (inclusive).

9. Older participants (Cohort 10) must be living in the community (includes long-term assisted living facilities but excludes long-term care nursing facilities).

10. If applicable, older-adult participants (Cohort 10) diagnosed with chronic cardio- or metabolic diseases must have the condition well controlled (in the opinion of the investigator) to include a stable regimen for four (4) weeks prior to Dose Day 1. Some medications are permitted to treat common disorders, such as but not limited to hypertension, type II diabetes, dyslipidemia, and hypothyroidism.

11. Participants must have low likelihood of brain amyloid presence based on an amyloid probability score 2 (APS2) of \< 47.5 calculated by PrecivityAD2™ test using the plasma sample collected at screening visit.

Participants meeting any of the following criteria must be excluded in the study:

  1. History of any current or gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, ophthalmologic, hematological or allergic disease or metabolic disorder.

    Note: Older participants in Cohort 10 may be eligible if the chronic condition is well controlled per opinion of the clinical investigator.

  2. Use of any concomitant medications is prohibited, other than prescribed birth control methods stable 4 weeks prior to screening.

    Note: Older participants in Cohort 10 who are taking stable dose regimen (4 weeks prior to Dose Day 1) may be eligible upon review and approval by the Medical Monitor.

  3. A history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the (DSM).
  4. Any evidence of current suicidal ideation or any previous suicide attempt as evaluated by the Columbia-Suicide Severity Rating Scale (C-SSRS).
  5. Diagnosis of a neurodegenerative disease or dementia, including but not limited to Alzheimer's disease (AD), Parkinson's disease and Huntington's disease.
  6. A history of a seizure disorder.
  7. Impaired hepatic function with any of the following lab abnormalities on screening:

    1. (ALT/SGPT) > 1.2X the (ULN)
    2. Aspartate aminotransferase (AST/SGOT) values > 1.2X ULN
    3. Alkaline phosphatase (ALP) values > 1.2X ULN
    4. Total > 1X ULN (excepting Gilbert's syndrome which is not an exclusion)
  8. Renal function with an estimated (eGFR) less than 90 mL/minute/1.73 m2 Note: less than 80 mL/minute/1.73 m2 in older participants enrolling in Cohort 10.
  9. Presence of crystalluria in urinalysis at screening.
  10. A clinically significantly abnormal 12-lead result, including but not limited to: heart rate \< 50 or > 100 beats per minute (bpm), QRS > 160 ms, > 450 ms in men \& 460 ms in women, or any clinically significant arrhythmia including Mobitz type II second-degree atrioventricular (AV)(Hay block) block and bifascicular block.
  11. A seated systolic blood pressure of \< 100 or > 140 millimeters of mercury (mm Hg) or diastolic blood pressure of \< 60 or > 90 mm Hg.

    1. Two readings should be taken approximately 1 minute apart and the average of the two will be applied.
    2. If the average is outside of the approved range, the procedure will be repeated following a brief rest.
  12. Postural change at 3 min upon standing from seated position of:

    1. > 20 mm Hg systolic or > 10 mm Hg diastolic decrease in blood pressure
    2. > 30 bpm increase in heart rate
  13. Cancer or malignant tumor within the past 3 years, except patients who underwent potentially curative therapy with no evidence of recurrence. Patients with stable untreated prostate cancer or skin cancers are not excluded.
  14. Current acute or chronic Hepatitis A, B, C or infection.
  15. Alcohol abuse, alcohol dependence, or drug abuse in the past 5 years per most current version of the DSM.
  16. Participation in another clinical trial with an agent and have taken at least one dose of study medication, unless unblinded on placebo, within 3 months (12 weeks) or 5 drug half-lives (whichever is longer), prior to screening. (The end of a previous investigational trial is the date the last dose of an investigational agent was taken).
  17. Previous treatment (within 1 year) with an investigational small molecule with anti-amyloid properties or passive immunization against Aβ or previous treatment with an active immunization against amyloid.
  18. Positive result from a urine drug test at screening (screened for Amphetamines, Barbiturates, Cocaine metabolites, 3,4-Methylenedioxymethamphetamine (MDMA), Tricyclic Antidepressants (TCA), Phenylcyclohexyl Piperidine (PCP), Cotinine, Opiates, Benzodiazepines, Cannabinoids (THC), Methamphetamine, Methadone, Oxycodone (OXY)).
  19. Not willing to abstain from consuming products containing caffeine (including chocolate), xanthine, citrus or alcohol from Day 1 through the end of the PK study.
  20. SAD Cohorts 5, 6 and MAD Cohorts 9, 10: to lumbar puncture (LP) This includes but is not limited to participants with a known allergy to the local anesthetics used in the LP, infection or inflammation of the skin or skin disease at or in proximity to the LP site; abnormal coagulation parameters, including count, , PT and/or PTT, History of lumbar spine surgery or chronic low back pain for participants in the SAD Cohorts 5 and 6 and the MAD Cohorts 9 and 10.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort 01: 20 mg

    Healthy adult participants receiving a single dose in the SAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 02: dose to be determined

    Healthy adult participants receiving a single dose in the SAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 03: dose to be determined

    Healthy adult participants receiving a single dose in the SAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 04: dose to be determined

    Healthy adult participants receiving a single dose (x2) in the SAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 05: dose to be determined

    Healthy adult participants receiving a single dose (x2) in the SAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 06: dose to be determined

    Healthy adult participants receiving a single dose in the SAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 07: dose TBD

    Healthy adult participants receiving a multiple dose in the MAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 08: dose TBD

    Healthy adult participants receiving a multiple dose in the MAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 09: dose TBD

    Healthy adult participants receiving a multiple dose in the MAD study.

    Drug: GSM-779690T · Other: Placebo

  • Experimental
    Cohort 10: dose TBD

    Healthy older-adult participants receiving a multiple dose in the MAD study.

    Drug: GSM-779690T · Other: Placebo

Interventions

  • DrugGSM-779690T

    Opaque capsules for oral consumption.

  • OtherPlacebo

    Opaque capsules for oral consumption.

06

What researchers measure

Primary outcomes

  1. Number and percentage of participants reporting treatment-emergent adverse events and serious adverse events after single and multiple oral doses of GSM-779690-T

    Treatment emergent adverse events and serious adverse events will be summarized for each treatment group. The frequencies of treatment emergent adverse events and serious adverse events between the participants in each group will be compared.

    Time frame: From enrollment through study completion, approximately 7 days in groups 1, 2, 3, and 6; 14 days in groups 4 and 5; and 21 days in groups 7, 8, 9, and 10.

Other outcomes

  1. Pharmacokinetic parameter of area under the curve (AUC) calculation after single and multiple oral doses of GSM-779690-T

    Time frame: SAD Groups 1, 2, 3, 6 Days 0 to 7 post-dose (plasma); SAD Groups 4 and 5 Days 0 to 10 post-dose (plasma), Days 1 to 2 post-dose (CSF); MAD Groups 7, 8, 9 and 10 Days 0 to 16 post-dose (plasma), Days 14 to 15 post-dose (CSF).

  2. • Pharmacokinetic Parameter of maximum plasma concentration (cmax) calculation after single and multiple oral doses of GSM-779690-T

    Time frame: SAD Groups 1, 2, 3, 6 Days 0 to 7 post-dose (plasma); SAD Groups 4 and 5 Days 0 to 10 post-dose (plasma), Days 1 to 2 post-dose (CSF); MAD Groups 7, 8, 9 and 10 Days 0 to 16 post-dose (plasma), Days 14 to 15 post-dose (CSF).

  3. Pharmacokinetic Parameter of time to maximum plasma concentration (tmax) calculation after single and multiple oral doses of GSM-779690-T

    Time frame: SAD Groups 1, 2, 3, 6 Days 0 to 7 post-dose (plasma); SAD Groups 4 and 5 Days 0 to 10 post-dose (plasma), Days 1 to 2 post-dose (CSF); MAD Groups 7, 8, 9 and 10 Days 0 to 16 post-dose (plasma), Days 14 to 15 post-dose (CSF).

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Jul 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Sep 4, 2025
StartEst.
Nov 9, 2025
Primary completionEst.
Jul 11, 2026
CompletionEst.
Jul 11, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07155980
Lead sponsor
Acta Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Nov 9, 2025 (estimated)
Primary completion
Jul 11, 2026 (estimated)
Completion
Jul 11, 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

Doug Galasko, MD
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion